Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Tao Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3818-5675; OpenAlex author ID A5101430890. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 4 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 9

  1. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2024.216607↗
  2. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  3. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. First author DOI 10.1016/j.pan.2020.02.008↗
  4. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0486-z↗
  5. Author Correction: piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0520-1↗
  6. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.02.010↗
  7. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Co-author DOI 10.1038/s41416-019-0595-2↗
  8. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1298↗
  9. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Co-author DOI 10.1186/s12943-017-0689-5↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 7 shared papers, 2017–2024 · strength 0.71
  2. Xueli Bai · 5 shared papers, 2017–2020 · strength 0.43
  3. Qi Zhang · 3 shared papers, 2020–2024 · strength 0.39
  4. Jin Li · 3 shared papers, 2020–2024 · strength 0.39
  5. Jianfeng Lü · 1 shared paper, 2024 · strength 0.19
  6. Jian Zhang · 1 shared paper, 2024 · strength 0.19
  7. Xiang Li · 2 shared papers, 2019–2020 · strength 0.18
  8. Tao Ma · 2 shared papers, 2019–2020 · strength 0.18
  9. Risheng Que · 2 shared papers, 2019–2020 · strength 0.18
  10. Wenhui Lou · 2 shared papers, 2020 · strength 0.18
  11. Yingbin Liu · 2 shared papers, 2020 · strength 0.18
  12. Feng Li · 2 shared papers, 2020 · strength 0.18
  13. Peng Yuan · 2 shared papers, 2020 · strength 0.18
  14. Yefei Rong · 2 shared papers, 2020 · strength 0.18
  15. Mo‐Fang Liu · 2 shared papers, 2020 · strength 0.18
  16. Qi Chen · 2 shared papers, 2017–2020 · strength 0.18
  17. Jiaqi Yang · 2 shared papers, 2017–2020 · strength 0.16
  18. Qihan Fu · 2 shared papers, 2017–2019 · strength 0.15
  19. Jianxin Wang · 1 shared paper, 2020 · strength 0.11
  20. Xiao Zhi · 1 shared paper, 2020 · strength 0.09
  21. Jian Zhang · 1 shared paper, 2020 · strength 0.09
  22. Qi Chen · 1 shared paper, 2020 · strength 0.09
  23. Wei Chen · 1 shared paper, 2020 · strength 0.09
  24. Tingbo Liang · 1 shared paper, 2020 · strength 0.09
  25. Jianying Lou · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.